
BioUtah CEO, Kelvyn Cullimore, Makes the Rounds in DC
March 26, 2026
BioUtah President and CEO, Kelvyn Cullimore, was in Washington, D.C. this week to meet with elected officials to advocate on behalf of Utah’s life sciences industry. Cullimore met with all members of the Utah Congressional delegation – Senators Mike Lee (R-UT) and John Curtis (R-UT), and Representatives Blake Moore (R-UT), Burgess Owens (R-UT), Celeste Maloy (R-UT), and Mike Kennedy (R-UT). Topics included support for legislation to streamline Medicare reimbursement for FDA-designated Breakthrough Products and SBIR funding. Cullimore raised concerns about the administration’s efforts to codify Most-Favored-Nation drug pricing – just another drug price control mechanism that will impede innovation and patient access to critical medicines.
“It was a pleasure meeting with the Utah delegation, who continue to show strong support for our industry’s policy priorities,” said Cullimore. “They are truly engaged partners, eager to learn more about the booming life sciences sector in Utah and responsive to our concerns.”
Cullimore, on March 25, also attended the Biotech Across America State Symposium, focusing on leveraging state and local strengths in biotechnology for national security.
Recent News
- Rep. Celeste Maloy Tours BIOS, Neurotech Innovation
- U.S. FDA Accepts Teva’s New Drug Application (NDA) and Grants Priority Review for Ecopipam for Pediatric Patients with Tourette Syndrome
- Sera Prognostics Appoints Scott Gleason CFO
- Merit Medical Announces Global Operations Leadership Transition
- Utah Life Sciences Innovation Caucus Breakfast
- Curavit Expands Clinical Research Capabilities with Acquisition of Lindus Health CRO Assets, Accelerating Global Trial Execution for Life Science Sponsors














